Trial Profile
A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Sponsors Procter & Gamble
- 24 Jun 2011 New trial record